{"id":5892,"date":"2021-04-16T18:40:14","date_gmt":"2021-04-16T16:40:14","guid":{"rendered":"https:\/\/syva.es\/for-once-let-us-talk-about-business\/"},"modified":"2021-04-16T18:40:14","modified_gmt":"2021-04-16T16:40:14","slug":"for-once-let-us-talk-about-business","status":"publish","type":"post","link":"https:\/\/syva.es\/en\/for-once-let-us-talk-about-business\/","title":{"rendered":"For once, let us talk about business!"},"content":{"rendered":"

For the second year in a row, our Managing Director Cesar Carnicer was interviewed by Joseph Harvey (Animal Pharm), business analyst for IHS Markit.<\/p>\n

For sure, in these times of pandemic, we all need to read, hear and talk about things that are going well and bring a little positivity to our daily lives. Although we are rather discreet on the subject, for once we are going to talk about Syva from a more ‘business’ angle.<\/p>\n

As this economic analyst’s evocatively titled article points out: ‘Syva’s investment in burgeoning vaccine business undeterred by pandemic’, Syva has remained solid despite the sanitary threat and has been well advised to continue developing its vaccine production activities, which now account for a third of its turnover and which reached a decisive turning point in 2019 with the launch of its multi-strain vaccine against blue tongue disease.<\/p>\n

If we had to give some achievements of Syva’s activity in 2020, it is<\/p>\n